Serina Therapeutics Adds Biotech Veteran Farrell Simon to Board — Serina Therapeutics, Inc.

Event summary

Farrell Simon, Pharm. D., joins Serina Therapeutics' Board of Directors effective July 22, 2026.
Simon currently serves as Chief Commercial Officer at Trevi Therapeutics and has raised over $400M in financings.
He will also serve on the Audit and Compensation Committees.
Serina's SER-252 Phase 1b trial for Parkinson’s disease is ongoing with plans to expand to South Korea and Taiwan.

The big picture

Serina Therapeutics is bolstering its governance with a seasoned biotech executive as it navigates the critical Phase 1b trial for SER-252. Simon's track record in commercial strategy and capital raising suggests a strategic focus on scaling the POZ platform through partnerships, aligning with broader industry trends toward modular drug delivery technologies. The appointment comes at a pivotal stage for Serina as it seeks to validate its lead asset while exploring broader applications of its proprietary technology.

What we're watching

Commercial Strategy: How Simon's experience in commercial strategy and business development will influence Serina’s partnering and M&A efforts.
Clinical Execution: The pace at which SER-252 advances through Phase 1b trials and the potential for regulatory milestones.
Platform Expansion: Whether Serina can leverage its POZ platform technology to secure additional partnerships beyond Pfizer.